MCID: HYP098
MIFTS: 65

Hypereosinophilic Syndrome

Categories: Rare diseases, Immune diseases, Blood diseases

Aliases & Classifications for Hypereosinophilic Syndrome

MalaCards integrated aliases for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 12 72 49 36 51 41 14 69
Eosinophilia 12 72 28 51 41 69
Hes 49 44
Disseminated Eosinophilic Collagen Disease 69
Hypereosinophilic Syndrome, Idiopathic 49
Idiopathic Hypereosinophilic Syndrome 69
Eosinophilic Leukocytosis 12
Eosinophilic Disorder 69

Classifications:



External Ids:

Disease Ontology 12 DOID:999
ICD10 32 D72.1
ICD9CM 34 288.3
KEGG 36 H01599

Summaries for Hypereosinophilic Syndrome

NIH Rare Diseases : 49 Hypereosinophilic syndrome (HES) refers to a rare group of conditions that are associated with persistent eosinophilia with evidence of organ involvement. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases. Management varies based on the severity of the condition and whether or not an underlying cause has been identified but generally includes imatinib or corticosteroids as an initial treatment. Last updated: 6/13/2017

MalaCards based summary : Hypereosinophilic Syndrome, also known as eosinophilia, is related to primary hypereosinophilic syndrome and hypereosinophilic syndrome, idiopathic, and has symptoms including gastrointestinal gas, snoring and nausea and vomiting. An important gene associated with Hypereosinophilic Syndrome is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisolone and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 4.5×109/L... more...

Related Diseases for Hypereosinophilic Syndrome

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 primary hypereosinophilic syndrome 33.8 FGFR1 FIP1L1 PDGFRA PDGFRB
2 hypereosinophilic syndrome, idiopathic 33.5 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
3 endomyocardial fibrosis 32.6 FIP1L1 PDGFRA
4 chronic eosinophilic leukemia 30.7 ABL1 FGFR1 FIP1L1 IFNA1 KIT PDGFRA
5 eosinophilic colitis 30.7 PRG2 RNASE3
6 churg-strauss syndrome 30.2 CCL17 IL5 RNASE3
7 loeffler endocarditis 30.2 FIP1L1 IL5 PDGFRA RNASE3
8 myelofibrosis 30.0 IFNA1 IL3 KIT PDGFRB
9 systemic mastocytosis 30.0 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
10 gastroenteritis 29.9 CCL11 CXCL8 IFNA1 IL5 RNASE3
11 wells syndrome 29.9 CXCL8 IL2RA IL5 RNASE3
12 eosinophilic meningitis 29.6 CCL11 IL13 IL5
13 mast cell disease 29.6 IL13 IL5 KIT PDGFRA PDGFRB
14 parasitic helminthiasis infectious disease 29.6 IL13 IL5 RNASE3
15 bullous pemphigoid 29.5 CCL11 CCL17 IL5 RNASE3
16 cutaneous t cell lymphoma 29.5 CCL17 IFNA1 IL2RA
17 mycosis fungoides 29.4 CCL17 IFNA1 IL2RA IL5
18 eosinophilic gastritis 29.3 CCL11 IL13 IL3 IL5
19 esophagitis, eosinophilic, 1 29.2 CCL11 EPX IL13 IL5 RNASE3
20 esophagitis 29.1 CCL11 CXCL8 IL13 IL5
21 eosinophilic gastroenteritis 29.1 CCL11 CSF2 EPX IL3 IL5 RNASE3
22 pneumonia 29.1 CCL11 CXCL8 IL13 IL5
23 myeloid leukemia 28.6 ABL1 CSF2 IL3 KIT
24 leukemia, chronic myeloid 28.1 ABL1 CSF2 IFNA1 IL3 KIT PDGFRA
25 eosinophilic pneumonia 27.7 CCL11 CCL17 CSF2 IL13 IL3 IL5
26 dermatitis 27.7 CCL11 CCL17 IGES IGHE IL13 IL5
27 asthma 25.6 CCL11 CCL17 CSF2 CXCL8 EPX IGES
28 eosinophilia, familial 12.4
29 eosinophilia-myalgia syndrome 12.3
30 myeloproliferative disorder, chronic, with eosinophilia 12.3
31 lymphocytic hypereosinophilic syndrome 12.1
32 secondary hypereosinophilic syndrome 12.1
33 episodic angioedema with eosinophilia 11.0
34 pdgfra-associated chronic eosinophilic leukemia 10.6 FIP1L1 PDGFRA
35 reticular perineurioma 10.5 KIT PDGFRA
36 sm-ahnmd 10.5 FIP1L1 KIT PDGFRA
37 eosinophilic granuloma 10.5 EPX RNASE3
38 corneal dystrophy, subepithelial mucinous 10.5 FIP1L1 PDGFRA PDGFRB
39 pemphigoid gestationis 10.5 CCL11 IL5
40 desmoid tumor 10.4 KIT PDGFRA PDGFRB
41 heart sarcoma 10.4 KIT PDGFRA PDGFRB
42 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.4 FGFR1 PDGFRA PDGFRB
43 cellular neurofibroma 10.4 ABL1 PDGFRB
44 chronic eosinophilic pneumonia 10.4 CCL11 IL5 RNASE3
45 kimura disease 10.4 CCL11 IL5 RNASE3
46 fibrosarcoma of bone 10.4 KIT PDGFRA PDGFRB
47 intrinsic asthma 10.4 IL3 IL5 RNASE3
48 leukemia 10.3
49 leiomyosarcoma 10.3 KIT PDGFRA PDGFRB
50 cytokine deficiency 10.3 IL13 IL5

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to Hypereosinophilic Syndrome

Symptoms & Phenotypes for Hypereosinophilic Syndrome

UMLS symptoms related to Hypereosinophilic Syndrome:


gastrointestinal gas, snoring, nausea and vomiting, icterus, heartburn, edema, dyspepsia, diarrhea, coughing, constipation, chest pain, angina pectoris, abdominal pain, myalgia, pruritus

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.91 PDGFRA
2 Decreased viability GR00221-A-1 9.91 ABL1 FGFR1 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.91 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.91 PDGFRB ABL1 PDGFRA
5 Decreased viability GR00221-A-4 9.91 PDGFRA PDGFRB
6 Decreased viability GR00301-A 9.91 KIT
7 Decreased viability GR00342-S-1 9.91 PDGFRB ABL1
8 Decreased viability GR00342-S-2 9.91 ABL1
9 Decreased viability GR00342-S-3 9.91 ABL1
10 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
12 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FGFR1 KIT
13 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CSF2 CXCL8 IL2RA PDGFRB

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ABL1 KIT CCL11 PDGFRA CCL17 PDGFRB
2 digestive/alimentary MP:0005381 9.86 IL5 ABL1 KIT PDGFRA PDGFRB FGFR1
3 immune system MP:0005387 9.77 IL5 ABL1 KIT CCL11 PDGFRA CCL17
4 respiratory system MP:0005388 9.28 IL5 ABL1 KIT CCL11 PDGFRA CSF2

Drugs & Therapeutics for Hypereosinophilic Syndrome

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
2
Omalizumab Approved, Investigational Phase 4 242138-07-4
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4 glucocorticoids Phase 4,Phase 2,Phase 3
5 Respiratory System Agents Phase 4,Phase 2,Phase 3
6 Hormone Antagonists Phase 4,Phase 2,Phase 3
7 Hormones Phase 4,Phase 2,Phase 3
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
9 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3
10 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3
11 Immunoglobulins Phase 4,Phase 2,Phase 3
12 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
13 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
14 Antibodies Phase 4,Phase 2,Phase 3
15 Prednisolone acetate Phase 4,Phase 3
16 Methylprednisolone acetate Phase 4,Phase 3
17 Methylprednisolone Hemisuccinate Phase 4,Phase 3
18 Adrenergic Agents Phase 4,Phase 2
19 Adrenergic Agonists Phase 4,Phase 2
20 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
21 Adrenergic beta-Agonists Phase 4,Phase 2
22 Albuterol Phase 4,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
24 Neuroprotective Agents Phase 4,Phase 3
25 Tocolytic Agents Phase 4,Phase 2
26 Neurotransmitter Agents Phase 4,Phase 2
27 Anti-Allergic Agents Phase 4,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antiemetics Phase 4,Phase 3,Phase 2
30 Prednisolone hemisuccinate Phase 4,Phase 3
31 Prednisolone phosphate Phase 4,Phase 3
32 Protective Agents Phase 4,Phase 3,Phase 2
33 Autonomic Agents Phase 4,Phase 3,Phase 2
34 Bronchodilator Agents Phase 4,Phase 2
35
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
36
Daunorubicin Approved Phase 3 20830-81-3 30323
37
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
38
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
39
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
40
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
41
Thioguanine Approved Phase 3 154-42-7 2723601
42
Asparaginase Approved, Investigational Phase 3 9015-68-3
43
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
44 Analgesics Phase 3,Phase 2,Phase 1
45 Alkylating Agents Phase 3,Phase 2
46 N-Methylaspartate Phase 3
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Analgesics, Non-Narcotic Phase 3
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
50 Pharmaceutical Solutions Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 87)

# Name Status NCT ID Phase Drugs
1 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
4 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Unknown status NCT02559791 Phase 2, Phase 3 Placebo
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
7 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
10 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
11 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
12 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
13 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
14 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
15 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
16 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
17 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
18 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Active, not recruiting NCT03052725 Phase 3 reslizumab
19 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
20 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
21 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
22 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
23 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
24 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
25 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
26 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
27 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
28 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
29 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
30 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
31 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
32 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
33 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
34 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
35 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
36 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
37 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
38 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
39 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
40 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
41 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
42 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
43 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib Mesylate
44 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Recruiting NCT02071901 Phase 2 eltrombopag olamine
45 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Recruiting NCT02560610 Phase 2 OC000459;Placebo
47 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab
48 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2 Dexpramipexole
49 A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Terminated NCT00171860 Phase 2 imatinib mesylate
50 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: eosinophilia

Genetic Tests for Hypereosinophilic Syndrome

Genetic tests related to Hypereosinophilic Syndrome:

# Genetic test Affiliating Genes
1 Eosinophilia 28

Anatomical Context for Hypereosinophilic Syndrome

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

38
Myeloid, Bone, Heart, Skin, T Cells, Testes, Bone Marrow

Publications for Hypereosinophilic Syndrome

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 659)
# Title Authors Year
1
Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. ( 28986919 )
2018
2
Lymphocyte-Variant Hypereosinophilic Syndrome With Eosinophilic Myocarditis Treated With Steroids and Pegylated Interferon Alfa-2a. ( 29406050 )
2018
3
Repeated Prosthetic Mitral Valve Thrombosis in FlukeA Infection Induced Hypereosinophilic Syndrome. ( 28219563 )
2017
4
Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure. ( 28347583 )
2017
5
Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids. ( 28757367 )
2017
6
JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. ( 28111307 )
2017
7
Hypereosinophilic Syndrome With Eosinophilic Gastritis. ( 28491930 )
2017
8
Hypereosinophilic Syndrome After Liver Transplantation: A Case Report and a Review of the Literature. ( 28263223 )
2017
9
The right atrium in idiopathic hypereosinophilic syndrome : Insights from the 3D speckle tracking echocardiographic MAGYAR-Path Study. ( 29234843 )
2017
10
Aortic stiffness is increased in patients with hypereosinophilic syndrome being in early necrotic phase. ( 29312868 )
2017
11
Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. ( 28374041 )
2017
12
Hypereosinophilic syndrome: endomyocardial biopsy versus echocardiography to diagnose cardiac involvement. ( 28440714 )
2017
13
A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. ( 28401108 )
2017
14
Hypereosinophilic syndrome. ( 28052805 )
2017
15
Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay. ( 28577656 )
2017
16
When a death apparently associated to sexual assault is instead a natural death due to idiopathic hypereosinophilic syndrome: The importance of gamma-hydroxybutyric acid analysis in vitreous humor. ( 28527983 )
2017
17
Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes. ( 28337408 )
2017
18
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. ( 28378039 )
2017
19
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
20
Crescentic splinter haemorrhages reflect stroke pathophysiology in hypereosinophilic syndrome. ( 28891232 )
2017
21
Hypereosinophilic syndrome with central nervous system involvement: Two case reports and literature review. ( 28945486 )
2017
22
Eosinophilic myocarditis and hypereosinophilic syndrome. ( 28652675 )
2017
23
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. ( 28885361 )
2017
24
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. ( 27294613 )
2016
25
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
26
Hypereosinophilic Syndrome: A Case of Fatal LAPffler Endocarditis. ( 26904305 )
2016
27
Hypereosinophilic syndrome: cardiac diagnosis and management. ( 26567231 )
2016
28
Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman. ( 27158718 )
2016
29
Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. ( 27125206 )
2016
30
Cardiac involvement in hypereosinophilic syndrome. ( 26853257 )
2016
31
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. ( 27803915 )
2016
32
Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? ( 27915050 )
2016
33
Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- Extended follow-up. ( 27267517 )
2016
34
Idiopathic hypereosinophilic syndrome. ( 27728301 )
2016
35
Idiopathic Hypereosinophilic Syndrome Associated with Endomyocardial Fibrosis, Intracardiac Thrombi, Pulmonary and Skin Infiltration: A Case Report. ( 27617583 )
2016
36
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. ( 27887955 )
2016
37
Paediatric presentation of cardiac involvement in hypereosinophilic syndrome. ( 27329338 )
2016
38
Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome. ( 26780165 )
2016
39
Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome. ( 27231866 )
2016
40
Idiopathic hypereosinophilic syndrome resulting in distal aortic thromboembolism in a dog. ( 27723953 )
2016
41
Gastrointestinal and Hepatic Involvement in Hypereosinophilic Syndrome. ( 27733964 )
2016
42
Superficial femoral artery thromosis secondary to hypereosinophilic syndrome. ( 27728032 )
2016
43
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. ( 27185511 )
2016
44
Characterization of left atrial dysfunction in hypereosinophilic syndrome - Insights from the Motion analysis of the heart and great vessels by three-dimensional speckle tracking echocardiography in pathological cases (MAGYAR-Path) Study. ( 27118091 )
2016
45
Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. ( 26797802 )
2016
46
Non-Bacterial Thrombotic Endocarditis of Aortic Valve due to Hypereosinophilic Syndrome. ( 28290180 )
2016
47
Acute Paracoccidioidomycosis Due to Paracoccidioides brasiliensis S1 Mimicking Hypereosinophilic Syndrome with Massive Splenomegaly: Diagnostic Challenge. ( 27054891 )
2016
48
IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series. ( 28005278 )
2016
49
Idiopathic hypereosinophilic syndrome presenting as angina pectoris: A case report. ( 27521535 )
2016
50
Lymphocytic variant of Hypereosinophilic syndrome with deep vein thrombosis. ( 27728750 )
2016

Variations for Hypereosinophilic Syndrome

Expression for Hypereosinophilic Syndrome

Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for Hypereosinophilic Syndrome

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 ABL1 CCL11 CSF2 CXCL8 EPX FGFR1
2
Show member pathways
13.79 ABL1 CCL11 CCL17 CSF2 CXCL8 FGFR1
3
Show member pathways
13.66 CCL11 CCL17 CSF2 CXCL8 FGFR1 IFNA1
4
Show member pathways
13.55 CCL11 CCL17 CXCL8 FGFR1 IFNA1 IL13
5
Show member pathways
13.52 ABL1 CSF2 FGFR1 IL2RA IL3 IL5
6
Show member pathways
13.38 CCL11 CCL17 CSF2 CXCL8 FGFR1 IL13
7
Show member pathways
13.25 CCL11 CSF2 CXCL8 FGFR1 IFNA1 IGHE
8
Show member pathways
13.21 CCL11 CCL17 CSF2 CXCL8 FGFR1 IL13
9
Show member pathways
13.08 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
10
Show member pathways
13.04 CSF2 FGFR1 IL3 KIT PDGFRA PDGFRB
11
Show member pathways
13.04 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
12
Show member pathways
13.01 FGFR1 IFNA1 IL2RA IL3 KIT PDGFRA
13
Show member pathways
12.72 ABL1 FGFR1 KIT PDGFRA PDGFRB
14 12.62 ABL1 CXCL8 FGFR1 IFNA1 IL13 IL2RA
15
Show member pathways
12.6 CSF2 IGHE IL13 IL3 IL5
16
Show member pathways
12.49 FGFR1 IL13 IL2RA IL5 PDGFRA PDGFRB
17 12.41 CSF2 IL2RA PDGFRA PDGFRB
18
Show member pathways
12.39 CCL11 CCL17 CSF2 CXCL8 IL13 IL5
19
Show member pathways
12.38 CXCL8 KIT PDGFRA PDGFRB
20
Show member pathways
12.24 CSF2 IFNA1 IL13 IL2RA IL3 IL5
21
Show member pathways
12.21 CXCL8 IFNA1 IL13 IL3 IL5
22 12.17 ABL1 FGFR1 KIT PDGFRA PDGFRB
23
Show member pathways
12.15 CSF2 IL2RA IL3 IL5
24
Show member pathways
12.14 ABL1 CCL11 CXCL8 EPX IFNA1 IL13
25 12.05 CSF2 IL2RA IL3 IL5 KIT
26 12 CCL11 CXCL8 IGHE IL13
27 11.95 CSF2 IL2RA IL3 IL5 KIT
28 11.86 ABL1 IFNA1 IL2RA IL3
29 11.85 CSF2 CXCL8 IL13 IL5
30 11.83 IL13 IL2RA IL5 KIT
31
Show member pathways
11.83 CSF2 CXCL8 IL2RA IL3 IL5
32 11.82 FGFR1 PDGFRA PDGFRB
33
Show member pathways
11.78 FGFR1 KIT PDGFRB
34 11.74 FGFR1 KIT PDGFRA PDGFRB
35 11.72 CCL11 CCL17 IGHE IL5
36 11.72 CCL11 CSF2 CXCL8 IL13 IL5
37
Show member pathways
11.7 ABL1 KIT PDGFRA PDGFRB
38 11.56 CCL11 CCL17 IL13 IL2RA IL5
39 11.54 CSF2 CXCL8 IL13
40 11.53 CSF2 IL3 IL5
41 11.49 FGFR1 PDGFRA PDGFRB
42 11.46 FGFR1 PDGFRA PDGFRB
43 11.34 CSF2 IL13 IL3 IL5
44 11.21 CCL11 CCL17 CSF2 CXCL8 IL13 IL3
45 10.85 PDGFRA PDGFRB
46 10.77 IL13 IL5
47 10.64 CCL11 CCL17 CSF2 CXCL8 FGFR1 IL13

GO Terms for Hypereosinophilic Syndrome

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CCL17 CSF2 CXCL8 EPX IFNA1
2 external side of plasma membrane GO:0009897 9.46 IGHE IL13 IL2RA KIT
3 extracellular region GO:0005576 9.44 CCL11 CCL17 CSF2 CXCL8 EPX FGFR1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.97 ABL1 CSF2 FGFR1 KIT
2 positive regulation of cell proliferation GO:0008284 9.95 CSF2 FGFR1 IL3 IL5 KIT PDGFRA
3 positive regulation of cell migration GO:0030335 9.93 CCL11 KIT PDGFRA PDGFRB
4 regulation of receptor activity GO:0010469 9.92 CCL11 CCL17 CSF2 CXCL8 IFNA1 IL13
5 positive regulation of protein kinase B signaling GO:0051897 9.91 FGFR1 KIT PDGFRA PDGFRB
6 cytokine-mediated signaling pathway GO:0019221 9.91 IFNA1 IL3 IL5 KIT
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 ABL1 CCL11 CCL17 PDGFRA PDGFRB
8 inflammatory response GO:0006954 9.91 CCL11 CCL17 CXCL8 IL13 IL2RA IL5
9 protein autophosphorylation GO:0046777 9.89 ABL1 FGFR1 KIT PDGFRA PDGFRB
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 ABL1 IL3 IL5
11 cellular response to interleukin-1 GO:0071347 9.84 CCL11 CCL17 CXCL8
12 chemokine-mediated signaling pathway GO:0070098 9.83 CCL11 CCL17 CXCL8
13 cell chemotaxis GO:0060326 9.83 KIT PDGFRA PDGFRB
14 phosphatidylinositol phosphorylation GO:0046854 9.83 FGFR1 KIT PDGFRA PDGFRB
15 chemotaxis GO:0006935 9.83 CCL11 CCL17 CXCL8 PDGFRA PDGFRB
16 neutrophil chemotaxis GO:0030593 9.82 CCL11 CCL17 CXCL8
17 positive regulation of MAP kinase activity GO:0043406 9.81 FGFR1 KIT PDGFRB
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 FGFR1 KIT PDGFRA PDGFRB
19 phosphatidylinositol-mediated signaling GO:0048015 9.77 FGFR1 PDGFRA PDGFRB
20 positive regulation of DNA replication GO:0045740 9.77 CSF2 IL3 PDGFRA
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 CSF2 IL13 IL3 KIT
22 MAPK cascade GO:0000165 9.76 CSF2 FGFR1 IL2RA IL3 IL5 KIT
23 platelet-derived growth factor receptor signaling pathway GO:0048008 9.72 ABL1 PDGFRA PDGFRB
24 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 KIT PDGFRA PDGFRB
25 negative regulation of interleukin-10 production GO:0032693 9.68 EPX PRG2
26 cardiac myofibril assembly GO:0055003 9.67 PDGFRA PDGFRB
27 positive regulation of podosome assembly GO:0071803 9.67 CSF2 IL5
28 retina vasculature development in camera-type eye GO:0061298 9.65 PDGFRA PDGFRB
29 response to fluid shear stress GO:0034405 9.65 CSF2 PDGFRB
30 immune response GO:0006955 9.65 CCL11 CCL17 CSF2 CXCL8 IGHE IL13
31 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.64 PDGFRA PDGFRB
32 mast cell chemotaxis GO:0002551 9.62 CCL11 KIT
33 metanephric glomerular capillary formation GO:0072277 9.58 PDGFRA PDGFRB
34 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.58 ABL1 PDGFRB
35 defense response to nematode GO:0002215 9.57 EPX PRG2
36 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.56 PDGFRA PDGFRB
37 positive regulation of phospholipase C activity GO:0010863 9.56 FGFR1 KIT PDGFRA PDGFRB
38 peptidyl-tyrosine phosphorylation GO:0018108 9.23 ABL1 CSF2 FGFR1 IL3 IL5 KIT
39 protein phosphorylation GO:0006468 10.1 ABL1 CCL11 FGFR1 KIT PDGFRA PDGFRB

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.85 ABL1 FGFR1 KIT PDGFRA PDGFRB
2 cytokine activity GO:0005125 9.76 CCL11 CCL17 CSF2 CXCL8 IFNA1 IL13
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 FGFR1 KIT PDGFRA PDGFRB
4 chemokine activity GO:0008009 9.58 CCL11 CCL17 CXCL8
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
6 protein tyrosine kinase activity GO:0004713 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
7 platelet-derived growth factor receptor binding GO:0005161 9.48 PDGFRA PDGFRB
8 platelet-derived growth factor binding GO:0048407 9.43 PDGFRA PDGFRB
9 vascular endothelial growth factor binding GO:0038085 9.37 PDGFRA PDGFRB
10 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 FGFR1 IL2RA IL3 IL5 KIT

Sources for Hypereosinophilic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....